Genencor to Receive Patent for I-MUNE(R) Assay
21 Diciembre 2004 - 7:30AM
PR Newswire (US)
Genencor to Receive Patent for I-MUNE(R) Assay Technology Enables
Reduction Or Enhancement of Immune Response to Proteins and
Protein-Based Therapeutics PALO ALTO, Calif., Dec. 21
/PRNewswire-FirstCall/ -- Genencor International (NASDAQ:GCOR)
today announced that it has been notified a U.S. patent on its
I-MUNE(R) Assay will be granted on December 28, 2004. The assay is
a unique method of identifying the components of proteins that
induce an immunogenic response. The grant of the U.S. patent will
complement Genencor's previously granted European patent to I-MUNE
technology. Information provided by the assay is useful for
designing proteins with either enhanced immunogenicity (e.g., for
vaccines) or reduced allergenicity (e.g., potential for causing
allergic reactions) caused by proteins in a range of industrial and
consumer products and many of the increasing number of
pharmaceuticals that are made from recombinant proteins. U.S.
Patent No. 6,835,550 and European Patent No. 1073754 cover uses and
applications of this biological-based method that is often cited as
a benchmark for other model-based assays. Genencor scientists first
developed the IMUNE Assay for engineering its many industrial
enzymes used in a variety of applications including cleaning,
personal care, textiles and food processing. As biotechnology
companies have continued to advance protein-based pharmaceuticals,
the use of the IMUNE Assay as well as other techniques for
predicting immunogenicity have become key steps in the development
process. "The I-MUNE Assay has been acknowledged as a standard not
only for determining immunogenicity, but for providing the critical
information to re-engineer proteins to make them safer for consumer
and health care applications," said Michael Arbige, Ph.D.,
Genencor's senior vice president, Technology. " In our own
development efforts as well as in our work with pharmaceutical
companies, we have found the I-MUNE Assay to be a valuable tool in
creating new or re-engineered protein products." About Genencor
Genencor International, Inc. (http://www.genencor.com/) is a
diversified biotechnology company that develops and delivers
innovative products and services into the health care,
agri-processing, industrial and consumer markets. Using an
integrated set of technology platforms, Genencor's products deliver
innovative and sustainable solutions to improve the quality of
life. Genencor traces its history to 1982 and has grown to become a
leading biotechnology company, with over $380 million in year 2003
annual revenues. Genencor has principal offices in Palo Alto,
California; Rochester, New York; and Leiden, the Netherlands. This
press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. These include
statements concerning plans, objectives, goals, strategies, future
events or performance and all other statements which are other than
statements of historical fact, including without limitation,
statements containing words such as "believes," "anticipates,"
"expects," "estimates," "projects," "will," "may," "might" and
words of a similar nature. Such statements involve risks and
uncertainties that could cause actual results to differ materially
from those projected. Some important factors that could cause
actual results to differ include dependence on the efforts of third
parties, dependence on new and uncertain technology and its
uncertain application to new business ventures; regulatory actions
or delays, or uncertainties related to product development, testing
or manufacturing; ability to form and maintain strategic alliances;
ability to complete certain transactions and realize anticipated
benefits from acquisitions; dependence on certain intellectual
property rights of both Genencor and third parties, the competitive
nature of Genencor's industry; risks of obsolescence of certain
technology; and the high risk nature of efforts to develop products
for the health care market, including the achievement of successful
pre-clinical and clinical results. These and other risk factors are
more fully discussed in Genencor's most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q filed with the United
States Securities and Exchange Commission. The forward-looking
statements contained in this release represent the judgment of
Genencor as of the date of this press release. Genencor disclaims,
however, any intent or obligation to update any forward-looking
statements. DATASOURCE: Genencor International, Inc. CONTACT:
media, Valerie Tucker, +1-650-846-7571, or investors, Thomas
Rathjen, +1-650-846-5810, both for Genencor International, Inc. Web
site: http://www.genencor.com/
Copyright
Genencor International (NASDAQ:GCOR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Genencor International (NASDAQ:GCOR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025